RecruitingPhase 2NCT01898416

Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors

Studying Desmoid tumor

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
michal roll
Principal Investigator
Jacob Bickels, MD/PhD
Tel-Aviv Sourasky Medical Center
Intervention
5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.(drug)
Enrollment
140 enrolled
Eligibility
18 years · All sexes
Timeline
2013 – 2026

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01898416 on ClinicalTrials.gov

Other trials for Desmoid tumor

Additional recruiting or active studies for the same condition.

See all trials for Desmoid tumor →

← Back to all trials